Close Menu

NEW YORK — OpGen said in a filing with the US Securities and Exchange Commission today that it intends to undertake a 20-for-1 reverse stock split.

The disclosure comes less than a week after the Gaithersburg, Maryland-based developer of antibiotic-resistance testing technology said that it had been notified by the Nasdaq that it was out of compliance with the exchange's $2.5 million minimum shareholder equity requirement and faced delisting.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Sponsored by

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.